Filing Analysis
PAVMmed Inc. held its annual meeting of stockholders on June 24, 2026, where shareholders approved the election of two directors and amendments to the Employee Stock Purchase Plan (ESPP). The appointment of CBIZ CPAs P.C. as independent auditors for the fiscal year ending December 31, 2026, was also ratified.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual meeting held on June 24, 2026, with approximately 59.6% of shares outstanding represented in person or by proxy.
- Re-election of Ronald M. Sparks and Timothy Baxter to the Board of Directors (Class A).
- Approval of amendments to the Employee Stock Purchase Plan (ESPP) to increase available shares from 15,774 to 215,774.
- Approval of an increase in the annual ESPP evergreen provision limit from 5,556 to 500,000 shares.
- Ratification of CBIZ CPAs P.C. as independent registered certified public accounting firm for the year ending Dec 31, 2026.
PAVmed Inc. announced its financial results for the first fiscal quarter ended March 31, 2026, and provided a business update via a press release.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure)
- A press release was issued on May 15, 2026, and attached as Exhibit 99.1
- The report was signed by Dennis McGrath, President and CFO
PAVmed Inc. announced its financial results for the fiscal year ended December 31, 2025, and provided a business update via a press release on March 30, 2026.
📋 Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The report was filed on March 30, 2026, under Items 2.02 and 7.01.
- A press release detailing the results and business update is included as Exhibit 99.1.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
PAVmed Inc. stockholders approved several key proposals at a special meeting, including the issuance of common stock for the conversion of Series D Preferred Stock and debt refinancing. The meeting also resulted in a significant 1.5 million share increase to the company's 2014 Long-Term Incentive Equity Plan and a charter amendment regarding director removal.
🚩 Red Flags
- Significant potential dilution from the 700% increase in shares available under the 2014 Long-Term Incentive Equity Plan.
- Reliance on equity issuance (Series D Preferred and Convertible Notes) to refinance existing debt and redeem preferred stock.
- Charter amendment allowing director removal 'without cause' may indicate governance volatility or preparation for structural changes.
📋 Key Facts
- Stockholders approved the issuance of common stock upon conversion of 60,000 shares of Series D Preferred Stock sold in a February 3, 2026, private placement.
- Approval was granted for stock issuance related to an Amended and Restated Senior Secured Convertible Note used for debt refinancing.
- The 2014 Long-Term Incentive Equity Plan was amended to increase available shares by 1,500,000, raising the total from 213,517 to 1,713,517 shares.
- The Certificate of Incorporation was amended to allow the removal of any director with or without cause by a majority vote of outstanding voting power.
- The special meeting was held on March 27, 2026, with 54.1% of voting power represented.
PAVMmed Inc. completed a $30 million offering of Series D Convertible Preferred Stock and issued a new $15 million senior secured 2026 Note to refinance existing debt. The transaction involves significant punitive redemption terms for the preferred stock and high-interest debt.
🚩 Red Flags
- Extremely punitive redemption terms on Series D Preferred Stock (300%-500% of stated value).
- High-interest debt (15.0% cash interest) which may strain liquidity.
- Potential for significant dilution due to the convertible nature of both the preferred stock and the new note.
- Protective provisions allow Series D holders to appoint a director and require consent for certain corporate actions.
📋 Key Facts
- Raised $30 million through the sale of 30,000 shares of Series D Preferred Stock and warrants for an additional 30,000 shares.
- Initial conversion price for Series D Preferred Stock is set at $6.50 per share.
- Refinanced $8,414,890 in principal and interest of the 2022 Senior Secured Convertible Note into a new $15 million '2026 Note'.
- The 2026 Note carries a high 15.0% per annum cash interest rate and is secured by all existing and future assets (excluding Lucid subsidiary).
- Series D Preferred Stock includes a massive redemption premium: up to 500% of stated value if redeemed after February 3, 2028.
- The company must seek stockholder approval for issuances exceeding certain market limits.
PAVMmed Inc. has received notification from Nasdaq confirming that the company has regained compliance with the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
🚩 Red Flags
- Historical history of falling below minimum bid price requirements (non-compliance starting Jan 2025).
📋 Key Facts
- Nasdaq notified the Company on January 21, 2026, regarding compliance status.
- The Company met the $1 minimum bid price requirement from January 2, 2026, to January 19, 2026.
- This resolves a non-compliance issue that began around January 23, 2025, where the stock traded below $1 for 30 consecutive business days.
PAVMed Inc. has announced a 1-for-30 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. The split and a corresponding reduction in authorized common stock are scheduled to become effective on January 2, 2026.
🚩 Red Flags
- Reverse stock split (often viewed as a sign of distress or attempt to artificially inflate share price).
- Delisting risk: The company has already exhausted its initial and extended 180-day grace periods provided by Nasdaq.
- History of non-compliance with minimum bid requirements dating back to January 2025.
📋 Key Facts
- Reverse split ratio: 1-for-30.
- Effective Date: January 2, 2026, at 12:01 a.m. ET.
- Reason for split: To regain compliance with Nasdaq's $1.00 minimum bid price requirement after failing to do so during the initial and extended grace periods.
- Reduction in authorized shares: From 250,000,000 to 25,000,000 shares.
- New CUSIP number: 70387R 502.
- Fractional shares will be rounded up to one whole share; no cash in lieu of fractional shares will be paid.
PAVMmed Inc. stockholders approved a proposal to implement a reverse stock split and a significant reduction in authorized common stock during a special meeting held on December 5, 2025.
🚩 Red Flags
- Reverse stock split (typically used to boost share price for Nasdaq compliance or avoid delisting).
- Massive reduction in authorized shares (90% decrease) which may signal restructuring or capital management efforts.
- High voting threshold met, indicating a significant structural change to the equity base.
📋 Key Facts
- Stockholders representing ~65.8% of voting power were present at the Special Meeting.
- The Reverse Split ratio will range from 1-for-10 to 1-for-30, to be determined by the Board.
- Authorized common stock will be reduced from 250,000,000 shares to 25,000,000 shares.
- The amendment was approved with 19,310,685 votes 'For' and 974,164 votes 'Against'.
- The Board will effect the split by filing a certificate of amendment in Delaware as soon as practicable.
PAVmed Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2025, and provided a general business update.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Fiscal quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results and business updates.
- Signed by Dennis McGrath, President and Chief Financial Officer.
PAVMmed Inc.'s subsidiary, Lucid Diagnostics Inc., has closed a public underwritten offering of 28,750,000 shares at $1.00 per share. The transaction resulted in approximately $26.9 million in net proceeds intended for working capital and general corporate purposes.
🚩 Red Flags
- Significant dilution: The issuance of 28.75 million shares at a fixed price represents substantial potential dilution to existing shareholders.
📋 Key Facts
- Lucid Diagnostics Inc. (subsidiary) closed the sale of 28,750,000 shares of common stock.
- Offering price was $1.00 per share.
- The offering included a full exercise of underwriters' option for 3,750,000 shares.
- Net proceeds are expected to be approximately $26.9 million after underwriting discounts and expenses.
- Proceeds are earmarked for working capital and general corporate purposes.
PAVmed Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2025, and provided a general business update via press release.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Fiscal quarter ended June 30, 2025
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
- Signed by Dennis McGrath, President and CFO.
PAVMmed Inc. has received an extension from Nasdaq providing an additional 180 days to regain compliance with the minimum bid price requirement. The company failed to meet the $1.00 minimum bid price during its initial 180-day grace period.
🚩 Red Flags
- Delisting risk: The company is currently in a second-tier grace period for Nasdaq listing requirements.
- Persistent low stock price: The company has been unable to maintain the $1.00 minimum bid price since at least January 2025.
📋 Key Facts
- Nasdaq granted a second 180-day extension to regain compliance with the minimum bid price requirement (Rule 5550(a)(2)).
- The new deadline to achieve compliance is January 19, 2026.
- Compliance requires the closing bid price to be at least $1.00 per share for a minimum of ten consecutive business days.
- The company failed to regain compliance during the initial period that ended on July 22, 2025.
PAVmed Inc.'s majority-owned subsidiary, Veris Health Inc., completed a $2.5 million private equity offering of common stock and warrants to accredited investors. The proceeds are intended for the development of an implantable physiological monitor and general working capital.
🚩 Red Flags
- Down-round protection: The inclusion of anti-dilution adjustments (exercise price reduction and share increase) for investors if future raises occur at lower valuations is highly dilutive to existing shareholders.
- Restrictive covenants: A prohibition on incurring indebtedness until late 2026 may limit the subsidiary's operational flexibility.
📋 Key Facts
- Veris Health Inc. (subsidiary) raised approximately $2.5 million in gross proceeds.
- Offering included 1,785,714 shares of Veris Common Stock at $1.40 per share and 1,785,714 warrants.
- Warrants have an exercise price of $1.40 and become exercisable six months after issuance.
- Veris agreed to a covenant not to incur new indebtedness until December 23, 2026 (with certain exceptions).
- Investors received anti-dilution protection via full ratchet/down-round adjustment provisions if subsequent equity is raised at a lower valuation.
- PAVmed Inc. retains a 75.3% ownership stake in Veris on a fully-diluted basis post-offering.
PAVMmed Inc. held its annual meeting of stockholders on June 18, 2025, where shareholders approved several key proposals including the re-election of two directors and an amendment to increase shares available under the 2014 Long-Term Incentive Equity Plan.
🚩 Red Flags
- Significant non-votes/broker non-votes (over 5.3 million shares) across multiple items suggests high institutional or retail apathy or potential disagreement with management direction.
📋 Key Facts
- Annual Meeting held on June 18, 2025, with approximately 77.2% of shares outstanding represented.
- Re-election of Class C directors Lishan Aklog, M.D. and Michael J. Glennon was approved.
- Shareholders approved the issuance of common stock upon exercise of pre-funded warrants from a February 2025 private placement (Nasdaq Rule 5635 compliance).
- Approved amendment to the 2014 Long-Term Incentive Equity Plan to increase available shares by 2,500,000 (from 2,412,140 to 4,912,140).
- Ratified the appointment of Marcum LLP as independent auditor for the fiscal year ending Dec 31, 2025.
PAVmed Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025, and provided a general business update via press release.
📋 Key Facts
- Report date: May 15, 2025
- Reporting period: Fiscal quarter ended March 31, 2025
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
- Signed by Dennis McGrath, President and CFO.
PAVMmed Inc. announced a change in its independent registered public accounting firm due to the acquisition of Marcum LLP's attest business by CBIZ CPAs P.C. The filing notes that previous audit reports included an explanatory paragraph regarding the company's ability to continue as a going concern.
🚩 Red Flags
- Going concern language present in previous audit reports (FY 2023 and FY 2024).
- Auditor change occurring alongside existing going concern uncertainty.
📋 Key Facts
- Marcum LLP resigned as independent auditor on April 23, 2025.
- CBIZ CPAs P.C. was engaged as the new independent registered public accounting firm on April 23, 2025.
- The change is a result of CBIZ CPAs acquiring Marcum's attest business.
- Previous audit reports for fiscal years ended Dec 31, 2024, and Dec 31, 2023, included an explanatory paragraph regarding the company's ability to continue as a going concern.
PAVMed Inc. entered into an 'at-the-market' (ATM) sales agreement with Maxim Group LLC to facilitate the sale of common stock. The offering is capped at a maximum aggregate amount of $2,880,000.
🚩 Red Flags
- Dilutive potential: The ATM offering allows the company to issue new shares, which can dilute existing shareholders.
- Small offering size ($2.88M) relative to typical micro-cap needs suggests a continuous need for liquidity/working capital.
📋 Key Facts
- Entered into Sales Agreement with Maxim Group LLC on April 17, 2025.
- Maximum offering amount: $2,880,000 in shares.
- Agent commission is 3.0% of aggregate gross sales prices.
- Proceeds are intended for working capital and general corporate purposes.
- The offering is being conducted via an ATM program under a previously effective S-3 shelf registration (File No. 333-283994).
A subsidiary of PAVmed Inc., Lucid Diagnostics, has closed a public underwritten offering of 14,375,000 shares at $1.20 per share. The transaction resulted in approximately $16.1 million in net proceeds intended for working capital and general corporate purposes.
🚩 Red Flags
- Significant dilution: The issuance of over 14 million shares at a relatively low price point ($1.20) suggests potential shareholder dilution.
- Capital dependency: Use of proceeds for 'working capital' often indicates the company is relying on equity markets to fund ongoing operations.
📋 Key Facts
- Subsidiary Lucid Diagnostics closed the sale of 14,375,000 common shares on April 11, 2025.
- Offering price was $1.20 per share.
- The offering included the full exercise of underwriters' option for 1,875,000 shares.
- Net proceeds are expected to be approximately $16.1 million after underwriting discounts and expenses.
- Proceeds are earmarked for working capital and general corporate purposes.
PAVMmed Inc. filed an 8-K to announce its fiscal year 2024 financial results and provide a general business update via a press release.
🚩 Red Flags
- No specific red flags (such as going concern or auditor changes) are explicitly detailed in the text provided; however, full risk assessment requires the attached Exhibit 99.1.
📋 Key Facts
- Report date: March 25, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes an announcement of financial results and a business update via Exhibit 99.1.
- Signed by Dennis McGrath, President and CFO.
PAVmed Inc.'s subsidiary, Lucid Diagnostics Inc., has closed a common stock offering of 13,939,331 shares at $1.10 per share. The net proceeds are expected to be approximately $14.5 million, intended for working capital and general corporate purposes.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 13.9 million shares.
- Low share price ($1.10) often associated with micro-cap volatility and potential delisting risks if minimum bid requirements are not met.
📋 Key Facts
- Lucid Diagnostics Inc. (subsidiary) closed the sale of 13,939,331 shares of common stock on March 5, 2025.
- Offering price: $1.10 per share.
- Estimated net proceeds: approximately $14.5 million after fees and expenses.
- Use of proceeds: working capital and general corporate purposes.
- The offering was conducted via a shelf registration statement on Form S-3.
PAVMmed Inc. and its subsidiary Veris Health completed a $2.37 million equity offering of common stock and pre-funded warrants to accredited investors at $0.7115 per share. The capital is intended for the development of an implantable physiological monitor and general working capital.
🚩 Red Flags
- Significant dilution: Issuance of over 3.3 million total securities at a low price point.
- Restrictive covenants: The company is prohibited from incurring new debt until August 2026, severely limiting financial flexibility.
- Investor protection/Anti-dilution: Investors have protection against subsequent equity raises at lower prices and 100% participation rights in future offerings.
- Nasdaq compliance risk: The company must seek stockholder approval for the issuance of shares underlying the pre-funded warrants by June 30, 2025.
📋 Key Facts
- Offered 2,574,350 shares of common stock and 756,734 pre-funded warrants at $0.7115 per share/warrant.
- Total gross proceeds generated: $2.37 million (consummated Feb 21, 2025).
- Investors received approximately 677,143 shares of Veris Health Inc. common stock as part of the deal.
- Pre-funded warrants expire on February 18, 2030, with an exercise price of $0.001 per share.
- Company agreed to a covenant not to incur new indebtedness until August 18, 2026 (with certain exceptions).
- Investors granted 100% participation rights in future equity offerings.
PAVMmed Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement ($2.5 million) following a series of debt-to-equity conversions and expense reductions. However, the company is now subject to a one-year Mandatory Panel Monitor until February 14, 2026.
🚩 Red Flags
- Mandatory Panel Monitor: If the company falls out of compliance again before Feb 14, 2026, it faces immediate delisting without the option to submit a compliance plan.
- History of market value deficiencies (Rule 5550(b)(2)) and equity deficiencies (Rule 5550(b)(1)).
- Heavy reliance on debt-to-equity conversions to maintain listing status, which can lead to significant dilution.
📋 Key Facts
- Regained compliance with Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders' equity.
- Compliance achieved via: (1) exchange of $22.3M in secured convertible notes for Series C Preferred Stock on Jan 17, 2025; (2) issuance of Series C Preferred Stock for $2.653M on Jan 24, 2025; and (3) deconsolidation of Lucid Diagnostics Inc.
- The company was previously under a Nasdaq Hearings Panel extension until January 31, 2025.
- Subject to a Mandatory Panel Monitor for one year, ending February 14, 2026.
PAVMmed Inc. received a Nasdaq delisting notice due to its common stock closing bid price falling below $1.00 for 30 consecutive business days. Additionally, the company completed the sale of Series C Convertible Preferred Stock via debt cancellation totaling approximately $2.65 million.
🚩 Red Flags
- Delisting notice (Nasdaq compliance deficiency)
- Significant potential dilution via Series C Preferred Stock conversion
- Severe downward pressure on stock price indicated by the $0.2136 floor price in conversion terms
- Debt-for-equity swap/cancellation indicates liquidity or debt management issues
📋 Key Facts
- Nasdaq issued a deficiency notice on January 23, 2025, due to stock price falling below $1.00 (Nasdaq Rule 5550(a)(2)).
- The company has 180 days (until July 22, 2025) to regain compliance by achieving a $1.00 closing bid for 10 consecutive business days.
- Completed sale of 2,653 shares of Series C Convertible Preferred Stock on January 24, 2025, for ~$2.653 million.
- The transaction was executed via the cancellation of unsecured debt obligations.
- Potential dilution: Conversion at voluntary price ($1.068) would result in ~2.48M shares; conversion at floor price ($0.2136) could result in ~12.42M shares.
PAVMmed Inc. has completed a debt-for-equity exchange of $22.35 million in Senior Secured Convertible Notes for Series C Preferred Stock to address Nasdaq delisting threats. While the move aims to satisfy equity requirements, significant dilution risks remain due to potential massive share issuances upon conversion.
🚩 Red Flags
- Delisting risk: The company failed to meet the market value requirement and is operating under a final extension expiring Jan 31, 2025.
- Extreme Dilution Risk: Conversion of preferred stock could issue up to 104.6 million shares, significantly diluting existing common shareholders.
- Debt Restructuring/Distress: The conversion of $22.3M in debt into equity is a classic sign of liquidity distress and an attempt to clean up the balance sheet at the expense of equity holders.
📋 Key Facts
- On January 17, 2025, the company exchanged $22,347,543 in principal of Senior Secured Convertible Notes for Series C Convertible Preferred Stock.
- Remaining outstanding Convertible Note balance is approximately $6.6 million.
- The exchange was intended to help regain compliance with Nasdaq Listing Rule 5550(b)(1) regarding stockholders' equity (minimum $2.5 million).
- Potential dilution: Conversion at the voluntary price of $1.068 would result in ~20.9 million new shares; conversion at the floor price of $0.2136 could result in ~104.6 million new shares.
- The company is currently under a Nasdaq extension to regain compliance, valid until January 31, 2025.
PAVMed Inc. held a special meeting on January 15, 2025, where stockholders approved two critical proposals regarding the issuance of common stock upon conversion of Series C Preferred Stock to comply with Nasdaq Listing Rule 5635. Additionally, shareholders approved an amendment to increase authorized shares from 50 million to 250 million.
🚩 Red Flags
- Massive increase in authorized share capital (5x increase from 50M to 250M) suggests significant potential dilution for existing shareholders.
- The need for shareholder approval under Nasdaq Rule 5635 indicates the issuance of Series C Preferred Stock would otherwise violate Nasdaq's anti-dilution rules, signaling a highly dilutive financing event.
📋 Key Facts
- Stockholders representing ~53.8% of outstanding shares were present at the special meeting on January 15, 2025.
- Approval granted for issuance of common stock via conversion of Series C Preferred Stock under a Debt Exchange Agreement (dated Nov 15, 2024).
- Approval granted for issuance of common stock via conversion of Series C Preferred Stock under a Securities Purchase Agreement (dated Nov 20, 2024).
- The company expects to consummate these exchanges/sales prior to January 31, 2025.
- Shareholders approved an amendment to the Certificate of Incorporation to increase authorized common stock from 50,000,000 to 250,000,000 shares.
PAVmed Inc.'s subsidiary, Lucid Diagnostics Inc., closed a $21.95 million sale of Senior Secured Convertible Notes to accredited investors. A portion of the proceeds was immediately used to repay an existing 2023 convertible note.
🚩 Red Flags
- Use of proceeds for debt refinancing rather than pure growth capital (refinancing existing 2023 note).
- Issuance of convertible notes often leads to future equity dilution for existing shareholders.
- High level of leverage through 'Senior Secured' status of the new notes.
📋 Key Facts
- Lucid Diagnostics (subsidiary) raised $21.95 million in gross proceeds via Senior Secured Convertible Notes on November 22, 2024.
- Net proceeds after repayment of the 2023 Convertible Note totaled $18.3 million.
- The transaction involved a Registration Rights Agreement, a Guaranty, and a Security and Pledge Agreement.
- Proceeds were used to refinance/repay the Lucid 2023 Convertible Note issued on March 13, 2023.
PAVMmed Inc. entered into a Debt Exchange Agreement to swap $22.35 million of Senior Secured Convertible Notes for Series C Preferred Stock. This restructuring involves significant dilution and includes complex conversion features triggered by specific company events.
🚩 Red Flags
- Significant dilution potential via a massive increase in authorized common stock (from 50M to 250M shares).
- Presence of 'death spiral' conversion features (Alternate Conversion Price linked to 80% of VWAP) triggered by various events.
- Complex financial covenants, including a requirement to maintain cash flow on a break-even basis.
- The exchange is subject to stockholder approval and Nasdaq compliance rules regarding share issuance.
📋 Key Facts
- Exchange amount: $22,347,543 in principal and interest from Senior Secured Convertible Notes into 22,347 shares of Series C Preferred Stock.
- Series C terms: $1,000 stated value per share with a 7.875% annual dividend payable quarterly.
- Conversion price: Initial fixed conversion price of $1.068 per share for the Series C Preferred Stock.
- Alternate Conversion Price: Includes a 'death spiral' feature allowing conversion at 80% of VWAP in the event of a Triggering Event or failure to complete a Qualified Company Optional Redemption by March 31, 2025.
- Stockholder Approval: The company must seek approval for an increase in authorized common stock from 50 million to 250 million shares by January 31, 2025.
- Remaining Debt: Approximately $6.4 million in Convertible Notes remain outstanding after the exchange.
PAVMmed Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2024, and provided a general business update via press release.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Fiscal quarter ended September 30, 2024
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
- Registrant is listed as having Common Stock and Series Z Warrants registered on Nasdaq.
PAVMmed Inc. has received a Nasdaq staff determination letter for failure to maintain minimum market value requirements and is facing potential delisting. To address liquidity and equity issues, the company has deconsolidated Lucid Diagnostics Inc., which is expected to result in a $70 million non-cash gain.
🚩 Red Flags
- Delisting notice/failure to satisfy Nasdaq listing standards (Rule 5550(b)(2)).
- Significant negative stockholders' equity (deficit of $9.0M pro forma).
- Reliance on non-cash gains ($70M) to improve balance sheet metrics.
- Ongoing need to restructure existing senior secured convertible debt.
📋 Key Facts
- Deconsolidated Lucid Diagnostics Inc. effective September 10, 2024, due to loss of majority voting control.
- Expected to recognize an estimated non-cash gain of approximately $70 million in Q3 2024 from the deconsolidation.
- Received Nasdaq staff determination letter on September 10, 2024; securities face suspension and delisting unless a hearing is requested.
- The company failed to regain compliance with the $35 million market value rule by the September 3, 2024 deadline.
- Deconsolidation aims to help meet Nasdaq's $2.5 million minimum stockholders' equity requirement (pro forma shows deficit reducing from -$18.6M to -$9.0M).
- Two directors, James L. Cox and Joan B. Harvey, resigned effective September 10, 2024.
PAVMmed Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2024, and provided a general business update via a press release.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2024.
- Filing date: August 13, 2024.
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
- The report was signed by Dennis McGrath, President and CFO.
PAVMmed Inc. held its 2024 Annual Meeting of Stockholders on June 20, 2024. The meeting resulted in the successful election of two Class B directors and the ratification of Marcum LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 20, 2024.
- Stockholders representing approximately 58.5% of shares outstanding were present (in person or by proxy).
- James L. Cox, M.D. and Debra J. White were elected to the Board as Class B directors.
- The appointment of Marcum LLP as independent registered certified public accounting firm for the year ending Dec 31, 2024, was ratified.
PAVmed Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024, and provided a general business update via press release.
📋 Key Facts
- Reporting period: Fiscal quarter ended March 31, 2024.
- Filing date: May 14, 2024.
- The filing includes results of operations and financial condition (Item 2.02).
- Includes a business update via Exhibit 99.1.
PAVMmed Inc.'s majority-owned subsidiary, Lucid Diagnostics Inc., completed a Series B-1 Convertible Preferred Stock offering. The offering raised approximately $11.6 million from accredited investors.
🚩 Red Flags
- Convertible Preferred Stock often implies potential future dilution for existing shareholders upon conversion to common stock.
📋 Key Facts
- Effective date of agreement: May 1, 2024; Closing date: May 6, 2024.
- Lucid Diagnostics issued approximately 11,634 shares of Series B-1 Convertible Preferred Stock.
- Purchase price per share: $1,000.
- Total gross proceeds to Lucid Diagnostics: Approximately $11.6 million.
- The offering includes a Registration Rights Agreement for the resale of common stock issuable from the preferred shares.
PAVMmed Inc. announced that its majority-owned subsidiary, Veris Health Inc., entered into a Memorandum of Understanding (MOU) with a National Cancer Institute-Designated Comprehensive Cancer Center for a pilot program involving the Veris Cancer Care Platform.
📋 Key Facts
- Veris Health Inc. is a majority-owned subsidiary of PAVmed Inc.
- The agreement is a Memorandum of Understanding (MOU) to implement a pilot program.
- The program involves enrolling cancer patients on the Veris Cancer Care Platform.
- The partner is a National Cancer Institute-Designated Comprehensive Cancer Center.
PAVMmed Inc. entered into a letter agreement to extend the deadline for a $2,000,000 fee related to its existing senior secured convertible notes. The payment deadline has been moved from April 25, 2024, to June 15, 2024.
🚩 Red Flags
- Liquidity pressure: The company is unable to meet a $2M payment deadline by the original date of April 25, 2024.
- Debt restructuring/extension: Repeatedly extending terms and paying fees to avoid default on senior secured notes indicates significant cash flow constraints.
📋 Key Facts
- Agreement entered into on April 25, 2024.
- The $2,000,000 fee is related to the April 4, 2022, and September 8, 2022, senior secured convertible notes.
- The fee was originally agreed upon in March 2024 as consideration for a one-year maturity extension and waiver of certain financial covenants.
- The payment deadline for the $2,000,000 fee is extended from April 25, 2024, to June 15, 2024.
PAVMmed Inc.'s majority-owned subsidiary, Lucid Diagnostics, completed a Series B Preferred Stock offering and exchange involving accredited investors. The transaction included the sale of new preferred stock and the conversion/exchange of existing Series A and A-1 preferred shares.
🚩 Red Flags
- Complex multi-tier preferred stock exchange (Series A/A-1 into Series B) often indicates restructuring of debt or equity obligations.
- Potential future dilution for common shareholders due to the Registration Rights Agreement and convertible nature of the new shares.
📋 Key Facts
- Lucid Diagnostics (subsidiary) sold 12,495 shares of Series B Convertible Preferred Stock at $1,000 per share.
- Series B Investors exchanged 13,625 shares of Series A and 10,670 shares of Series A-1 for 31,790 shares of Series B Preferred Stock.
- The transaction closed on March 13, 2024.
- A Registration Rights Agreement was executed to cover the resale of Common Stock issuable from the Series B Preferred Stock.
PAVMmed Inc. entered into an amendment and waiver agreement with the holders of its senior secured convertible notes (April 2022 and September 2022 Notes). The agreement extends note maturities to 2025 and waives a critical market capitalization-based financial covenant in exchange for a $2 million cash payment.
🚩 Red Flags
- Liquidity strain: Requirement to pay $2M in cash by April 25, 2024.
- Covenant waiver: Indicates the company was at risk of breaching its debt-to-market-cap ratio covenant.
- Extension of debt: Maturity extensions suggest a need for more time to reach liquidity or growth milestones before repayment is due.
📋 Key Facts
- Maturity of April 4, 2022 Note extended to April 4, 2025.
- Maturity of September 8, 2022 Note extended to September 8, 2025.
- Waiver granted for financial covenant (Debt/Market Cap ratio < 30%) from Dec 1, 2023, to Aug 31, 2024.
- Condition of waiver: Company market capitalization must not be less than $75 million.
- Company must pay the note holder $2,000,000 in cash (or other agreed form) by April 25, 2024.
PAVMmed Inc. received a notice from Nasdaq stating the company's market value of listed securities fell below the $35 million minimum requirement for 30 consecutive business days. The company has been granted a 180-day period to regain compliance by September 3, 2024.
🚩 Red Flags
- Delisting notice due to failure to meet minimum market value requirements (Nasdaq Listing Rule 5550(b)(2)).
- Potential for delisting if compliance is not met by September 3, 2024.
- Market capitalization/liquidity issues indicated by the MVLS deficiency.
📋 Key Facts
- Nasdaq notification received on March 7, 2024.
- Market value of listed securities (MVLS) was below $35 million for the last 30 consecutive business days through March 6, 2024.
- The company has a 180-day window to regain compliance, expiring September 3, 2024.
- To regain compliance, MVLS must close at $35 million or more for at least ten consecutive business days.
- Securities (PAVM and PAVMZ) continue to trade uninterrupted on Nasdaq.
PAVmed Inc. completed a special pro rata dividend distribution of 3,331,747 shares of its majority-owned subsidiary, Lucid Diagnostics Inc., to its stockholders. This resulted in the company retaining approximately 65.2% ownership of Lucid Diagnostics.
🚩 Red Flags
- Adjustment of warrant exercise prices can lead to dilution or complex capital structure shifts, though here it is a standard anti-dilution adjustment.
📋 Key Facts
- Distributed 3,331,747 shares of Lucid Diagnostics Inc. common stock to PAVmed stockholders on February 15, 2024.
- The distribution represents approximately 6.9% of Lucid Diagnostics' outstanding common stock.
- PAVmed retains ~65.2% ownership in Lucid Diagnostics post-distribution.
- Dividend ratio: 0.37709668 shares of Lucid for every 1 share of PAVmed held as of January 15, 2024.
- The exercise price of Series Z Redeemable Warrants was adjusted downward from $24.00 to $23.48 per share due to the dividend.
PAVMmed Inc. issued an Information Statement regarding a special pro rata dividend of Lucid Diagnostics Inc. shares to its stockholders.
📋 Key Facts
- The Company is distributing approximately 3,331,771 shares of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc., via a special pro rata dividend.
- The distribution represents approximately 6.9% of Lucid Diagnostics' outstanding common stock.
- Following the distribution, PAVmed Inc. will retain ownership of approximately 65.2% of Lucid Diagnostics.
PAVMmed Inc. elected to receive $4,675,256 in fees and reimbursements from its majority-owned subsidiary, Lucid Diagnostics Inc., via the issuance of 3,331,771 shares of Lucid Diagnostics common stock.
🚩 Red Flags
- Related-party transaction involving the transfer of equity from a subsidiary to its parent company.
- Complexity in capital structure due to intercompany share issuances.
📋 Key Facts
- Transaction date: January 26, 2024
- Amount due to PAVmed: $4,675,256 in fees and reimbursements
- Payment method: Issuance of 3,331,771 shares of Lucid Diagnostics Inc. common stock
- Relationship: Lucid Diagnostics Inc. is a majority-owned subsidiary of PAVmed Inc.
PAVMmed Inc. has successfully regained compliance with the Nasdaq $1 minimum bid price requirement. This follows a period of non-compliance that began in late 2022.
🚩 Red Flags
- Historical history of delisting risk due to low stock price (minimum bid rule violation).
📋 Key Facts
- Nasdaq notified the company on January 5, 2024, that it has regained compliance with the $1 minimum bid price rule (Rule 5550(a)(2)).
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater from December 7, 2023, through January 5, 2024.
- The company had previously been in violation of the minimum bid requirement since at least December 28, 2022.